Septerna, Inc.
SEPNSepterna is a clinical-stage biotechnology company focused on discovering and developing oral small molecule drugs targeting G protein-coupled receptors (GPCRs).
Earnings
Next report
Aug 10, 2026 (In 4 weeks)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Septerna is a clinical-stage biotechnology company focused on discovering and developing oral small molecule drugs targeting G protein-coupled receptors (GPCRs). Utilizing its proprietary Native Complex Platform, the company aims to unlock the therapeutic potential of the approximately 75% of GPCR targets that remain undrugged. Its primary value proposition lies in replicating the native functional form of GPCRs outside of cells to enable industrialized, structure-based drug design for endocrine, metabolic, and inflammatory diseases.
Septerna is a pioneer in GPCR drug discovery, utilizing a first-of-its-kind platform to isolate and reconstitute GPCR proteins in their native functional form for industrial-scale drug design.
Questions, answered.
- What is Septerna, Inc.'s market cap?
- Septerna, Inc. (SEPN) has a market capitalization of $1.7B and trades on XNAS.
- What is Septerna, Inc.'s revenue and profitability?
- Septerna, Inc. generated $72.3M in trailing twelve-month revenue with a net loss of $36.0M, representing a net margin of -49.9%, with free cash flow of $98.3M. These figures are based on the Q1 2026 filing.
- Who are Septerna, Inc.'s competitors?
- Septerna, Inc.'s key competitors include Structure Therapeutics, Tectonic Therapeutic, Amgen, and others. These companies compete in similar markets and product categories.
- Who does Septerna, Inc. partner with?
- Septerna, Inc.'s notable partners include Novo Nordisk A/S, Ascendis Pharma.
- Where is Septerna, Inc. headquartered?
- Septerna, Inc. is headquartered in United States of America. It has been publicly traded since 2024.
